2015
Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil
Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD. Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 68: 152-161. PMID: 25415289, PMCID: PMC4294967, DOI: 10.1097/qai.0000000000000426.Peer-Reviewed Original ResearchConceptsGenotype resistance testingART initiationAntiretroviral treatmentART costsGenotype testingEvandro Chagas Clinical Research InstituteResistance prevalenceFirst-line ART initiationHIV Clinical CohortHIV treatment guidelinesIncremental cost-effectiveness ratioBaseline patient characteristicsEffective antiretroviral treatmentART-naive individualsLife expectancyClinical Research InstituteCost-effectiveness ratioImmune recoveryCD4 countViral suppressionHIV diseasePatient characteristicsTreatment guidelinesMean agePrimary resistance
2010
Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis
Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, Stoler AW, Freedberg KA, Investigators F. Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. PLOS Medicine 2010, 7: e1000382. PMID: 21209794, PMCID: PMC3014084, DOI: 10.1371/journal.pmed.1000382.Peer-Reviewed Original ResearchConceptsHIV treatment guidelinesART initiationTreatment guidelinesStage III/IV diseaseLong-term survival advantageEarly antiretroviral therapy initiationAntiretroviral therapy initiationLife expectancySouth African HIVResource limited settingsProjected life expectancyResource-limited settingsGreater life expectancyART regimensTherapy initiationAfrican HIVGuideline componentsSurvival advantageWHO recommendationsTenofovirRegimensStavudineSurvivalGuidelinesInitiation